FEZ1/LZTS1 protein expression in ovarian cancer

Journal of Cellular Physiology

Volumn 222, Issue 2, 2010, Pages 382-386

  Califano, Daniela ^a   Pignata, Sandro ^a   Pisano, Carmela ^a   Greggi, Stefano ^a   Laurelli, Giuseppe ^a   Losito, Nunzia Simona ^a   Ottaiano, Alessandro ^a   Gallipoli, Adolfo ^a   Pasquinelli, Rosa ^a   De Simone, Veronica ^b   Cirombella, Roberto ^c   Fusco, Alfredo ^d   Chiappetta, Gennaro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CROM Centro Ricerche Oncologiche Mercogliano   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; PROTEIN FEZ1; TAXANE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; LZTS1 PROTEIN, HUMAN; TAXOID;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 8; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE MAPPING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; AGE; CANCER STAGING; CARCINOMA; CHEMISTRY; DISEASE FREE SURVIVAL; DOWN REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CYTOPLASM; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RISK ASSESSMENT; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 73349110980     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21962     Document Type: Article

References (22)

1. Alberts DS. 1999. Treatment of refractory and recurrent ovarian cancer. Semin Oncol 26:8-14.
2. Arnold JM, Choong DY, Lai J, Campbell IG, Chenevix-Trench G. 2006. Mutation and expression analysis of LZTS1 in ovarian cancer. Cancer Lett 233:151-157.
3. Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, Chinault AC. 2001. LAPSE R1: A novel candidate tumor suppressor gene from 10q24.3. Oncogene 20:6707-6717.
4. Chen L, Zhu Z, Sun X Dong XY, Wei J, Gu F, Sun YL, Zhou J, Dong JT, Fu L. 2008. Down-regulation of tumor suppressor gene FEZ1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat 116:471-478.
5. International Collaborative Ovarian Neoplasm Group. 2002. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 360:505-515.
6. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM. 1999. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 96:3928-3933.
7. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM. 2001. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci USA 98:10374-10379.
8. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
9. Kumar A, Kumar DS, Prabhakaran VC, Prakash DR, Chakraborty S. 2007. Identification of genes associated with tumorigenesis of meibomian cell carcinoma by microarray analysis. Genomics 90:559-566.
10. Landis SH, Murray T, Bolden S, Wingo PA. 1998. Cancer statistics 1998. CA Cancer J Clin 48:6-29.
11. Mantel N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170.
12. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. 1996. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6.
13. Nonaka D, Fabbri A, Roz L, Mariani L, Vecchione A, Moore GW, Tavecchio L, Croce CM, Sozzi G. 2005. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. Cancer Res 65:1207-1212.
14. Ono K, Uzawa K, Nakatsuru M, Shiiba M, Mochida Y, Tada A, Bukawa H, Miyakawa A, Yokoe H, Tanzawa H. 2003. Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. Int J Oncol 23:297-302.
15. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. 2000. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708.
16. Teufel A, Weinmann A, Galle PR, Lohse AW. 2005. In silico characterization of LZTS3, a potential tumor suppressor. Oncol Rep 14:547-551.
17. Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF. 2002. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 8:2292-2297.
18. Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM, Baffa R. 2001. Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res 7:1546-1552.
19. Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM, Baffa R. 2002. FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 160:1345-1352.
20. Vecchione A, Galetti TP, Gardiman M, Ishii H, Giarnieri E, Pagano F, Gomella LG, Croce CM, Baffa R. 2004. Collecting duct carcinoma of the kidney: An immunohistochemical study of 11 cases. BMC Urol 4:11.
21. Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Donovan PJ, Croce CM. 2007. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell 11:275-289.
22. Welsh JB,Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. 2001. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98:1176-1181.